Navigation Links
Varian Medical Systems Schedules Third Quarter FY2009 News Release and Conference Call
Date:6/23/2009

PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for third quarter of fiscal year 2009 following the close of regular trading on Wednesday, July 29, 2009. The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT. The news release and information on the conference call webcast will be available on the company website at: www.varian.com/investor. Details on the conference call and replay follow:

    Teleconference:  Telephone from within the U.S.:

                     -- Dial 1-800-260-8140 and enter access code 31906727
                        prior to the call at 2:00 p.m.PT/5:00 p.m. ET.
                     Telephone from outside the U.S.:
                     -- Dial 1-617-614-3672 and enter access code 31906727
                        prior to the call at 2:00 p.m. PT/5:00 p.m. ET.
                     *Note: If the number of lines allocated to the call is
                     exhausted, the webcast or replay should be utilized.

    Replay:          The teleconference will be rebroadcast until 8:00 p.m.
                     ET, Friday, July 31, 2009 and can be accessed by phone
                     or Web link as follows:
                     -- Telephone from within the U.S.: Dial 1-888-286-8010 
                        and enter access code 35168740.
                     -- Telephone from outside the U.S.: Dial 1-617-801-6888
                        and enter access code 35168740.
                     -- Internet: Click on the "Quarterly Conference Call"
                        icon on the company's investor relations website at
                        www.varian.com/investor
                     -- Web conferences will be archived on the company
                        website for a year.

For automatic "e-mail alerts" regarding Varian news and events, investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.

For additional information contact Birgit Myles at 650-424-6637 or birgit.myles@varian.com.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America and Europe and in its 79 offices and facilities around the world. For more information, visit http://www.varian.com/.

    FOR INFORMATION CONTACT:
    Spencer Sias, (650) 424-5782
    Vice President, Corporate Communications
    and Investor Relations
    spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Varians RapidArc Radiotherapy Technology Enables Pioneering Cancer Treatments at Top Dutch Oncology Center
2. Leading Healthcare Group Selects Varian Medical Systems to Supply Cancer Treatment Technology for Treatment Centers Across the Western United States
3. Ovarian Cancer Breakthrough Heralds New Era of Treatment
4. Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan
5. Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
6. New Insights, Inroads Against Breast, Ovarian Cancers
7. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
8. Dream team targets key driver for breast, ovarian, endometrial cancers
9. Varian Medical Systems Introduces the PaxScan 3030+ X-Ray Image Detector for Interventional Angiography
10. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
11. The Diagnosis Every Woman Dreads - Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... , ... Rob Lowe is a popular actor that has been in many ... educational purpose as the host of the “Informed” series. The program focuses on many ... the series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Are you investing ... spike in water-related accidents and drownings during the summer. While most of us assume ... these situations occur every day. Very few people are taking the time to learn ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology: